Show simple item record

dc.contributor.authorLewis, Alexandra R
dc.contributor.authorPihlak, Rille
dc.contributor.authorMcNamara, Mairéad G
dc.date.accessioned2018-05-13T19:35:36Z
dc.date.available2018-05-13T19:35:36Z
dc.date.issued2018
dc.identifier.citationThe importance of quality-of-life management in patients with advanced pancreatic ductal adenocarcinoma.2018, 42(1): 26-39 Curr Probl Canceren
dc.identifier.issn1535-6345
dc.identifier.pmid29631711
dc.identifier.doi10.1016/j.currproblcancer.2018.01.013
dc.identifier.urihttp://hdl.handle.net/10541/621001
dc.description.abstractPancreatic ductal adenocarcinoma (PDAC) carries a poor prognosis, and as such, a focus on quality of life is vital. This review will discuss various aspects of quality of life in patients with PDAC and their treatment. Pancreatic exocrine and endocrine insufficiency may result in issues related to nutrition, and pain and fatigue are other common symptoms, and may be managed with pharmaceutical or nonpharmaceutical methods. It has also been reported that low mood is a particular problem for patients with PDAC compared to patients with other cancers; however, the data supporting this is inconsistent. Data regarding improvements in quality of life in patients with PDAC receiving chemotherapy is also reviewed, which in some cases suggests a benefit to chemotherapy, particularly in the presence of a radiological response. Furthermore, the importance of early palliative care is discussed and the benefits reported including improved quality of life and mood, reduced aggressive interventions at the end of life and improved survival. Areas for future development may include increased use of quality of life as a trial outcome and the use of patient-reported outcomes to improve symptomatic care of patients, and particularly in those receiving active systemic treatment.
dc.language.isoenen
dc.rightsArchived with thanks to Current problems in canceren
dc.titleThe importance of quality-of-life management in patients with advanced pancreatic ductal adenocarcinoma.en
dc.typeArticleen
dc.contributor.departmentDepartment of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UKen
dc.identifier.journalCurrent Problems in Canceren
html.description.abstractPancreatic ductal adenocarcinoma (PDAC) carries a poor prognosis, and as such, a focus on quality of life is vital. This review will discuss various aspects of quality of life in patients with PDAC and their treatment. Pancreatic exocrine and endocrine insufficiency may result in issues related to nutrition, and pain and fatigue are other common symptoms, and may be managed with pharmaceutical or nonpharmaceutical methods. It has also been reported that low mood is a particular problem for patients with PDAC compared to patients with other cancers; however, the data supporting this is inconsistent. Data regarding improvements in quality of life in patients with PDAC receiving chemotherapy is also reviewed, which in some cases suggests a benefit to chemotherapy, particularly in the presence of a radiological response. Furthermore, the importance of early palliative care is discussed and the benefits reported including improved quality of life and mood, reduced aggressive interventions at the end of life and improved survival. Areas for future development may include increased use of quality of life as a trial outcome and the use of patient-reported outcomes to improve symptomatic care of patients, and particularly in those receiving active systemic treatment.


Files in this item

This item appears in the following Collection(s)

Show simple item record